Quarterly report pursuant to Section 13 or 15(d)

Stockholders' equity (Tables)

v3.24.1.1.u2
Stockholders' equity (Tables)
9 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of warrants or rights
The activity related to warrants for the three and nine months ended March 31, 2024, is summarized, after giving effect to the Reverse Stock Split, as follows:
 
     Common
Stock from
Warrants
     Weighted-
average
Exercise
Price (per
share)
 
Outstanding at July 1, 2023
     2,348,039      $ 1.92  
Pre-funded
warrants issued August 11, 2023
     15,126,226      $ 0.0001  
Common warrants issued August 11, 2023
     16,002,175      $ 3.86  
  
 
 
    
 
 
 
Outstanding at September 30, 2023
     33,476,440      $ 1.98  
Pre-funded
warrants exercised
     25,000      $ 0.0001  
Series 2 warrants exercised
     20,000      $ 1.93  
  
 
 
    
 
 
 
Outstanding and exercisable at December 31, 2023
     33,431,440      $ 1.98  
Pre-funded
warrants exercised
     132,360      $ 0.001  
  
 
 
    
 
 
 
Outstanding and exercisable at March 31, 2024
     33,299,080      $ 1.99  
Schedule of equity awards
The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2024 is summarized as follows:
 
     Stock
Options
     Weighted-
average
Exercise
Price
     Weighted-
average
Remaining
Contractual
Term
     Aggregate
Intrinsic
Value
 
Outstanding at June 30, 2023
     107,993      $ 31.88        8.96 years      $ 11,888  
Granted
     1,076,538      $ 5.01        9.91 years        —   
Expired
     (1,800    $ 470.37        —         —   
Forfeited
     (353    $ 74.18        —         —   
  
 
 
    
 
 
    
 
 
    
 
 
 
Outstanding at March 31, 2024
     1,182,378      $ 6.73        9.76 years      $ 353,286  
Exercisable at March 31, 2024
     36,984      $ 57.30        6.78 years      $ 1,685  
Schedule of equity-based compensation expense
The classification of share-based compensation expense is summarized as follows:
 
     Three Months
Ended
     Nine Months
Ended
 
     March 31,  
(US$’000)    2024      2023      2024      2023  
Research and development
   $ 45      $ 27      $ 112      $ 87  
General and administrative
     147      44        264        238  
  
 
 
    
 
 
    
 
 
    
 
 
 
Total share-based compensation expense
   $ 192      $ 71      $ 376      $ 325